Antibody validation for improved reproducibility

For 30 years, Miltenyi Biotec has been committed to providing quality antibodies you can count on. Whether the antibodies are used for our market-leading MACS® MicroBead Technology or for flow cytometry applications, we apply rigorous production and quality control standards to make sure we deliver reliable products.

The reproducibility crisis 

In the past years, there has been a growing concern in the scientific community regarding reproducibility of experiments. This has been reflected in multiple publications and articles¹⁴. In this context, antibodies are considered as one of the key sources of inconsistency in results. 

As a manufacturer of antibodies, we take this topic very seriously and see our responsibility in serving the scientific community with validated and consistent tools. 

How does Miltenyi Biotec address the need for reproducible and validated antibodies? 

With the introduction of recombinant REAfinity™ Antibodies in 2012, we made a significant investment into improving quality and consistency of our REAfinity Recombinant Antibodies. The standardized antibody production process, starting from a defined DNA sequence, ensures high purity and lot-to-lot consistency. 

In addition, these recombinant antibodies do not display any undesired mixtures of heavy and light immunoglobulin chains, which is often the case with conventional hybridoma-derived antibodies⁵. These advantages make REAfinity Antibodies ideal tools for improving experimental reproducibility. 

Model of a REAfinity™ Recombinant Antibody

Three pillars of antibody validation

REAfinity Recombinant Antibodies are based on three pillars of validation: reproducibility, specificity, and sensitivity. Please find more detailed information for each validation method below:

Want to learn more about our antibody validation program and how to increase experimental reproducibility?  

General Information

Detailed Information

Please give your details for further inquiries.

* Mandatory field

Questions / Comments

Selected references

  1. Goodman, S.L. (2018) The antibody horror show: an introductory guide for the perplexed. N Biotechnol. 45: 9-13. 
  2. Baker M., (2015) Reproducibility crisis: Blame it on the antibodies. Nature 521(7552): 274-6.
  3. Bradbury A. and Plückthun A., (2015) Reproducibility: Standardize antibodies used in research. Nature 518(7537): 27-9. 
  4. Journals unite for reproducibility. (2014) Nature 515(7525): 7.
  5. Bradbury A.R.M. et al., (2018) When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. Mab 10(4): 539-546